Celcuity Inc. (NASDAQ:CELC) Receives Average Recommendation of “Buy” from Brokerages

Shares of Celcuity Inc. (NASDAQ:CELC) have earned an average rating of “Buy” from the seven research firms that are presently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $28.67.

CELC has been the subject of a number of analyst reports. Craig Hallum restated a “buy” rating and issued a $27.00 price objective (up from $25.00) on shares of Celcuity in a research note on Thursday, May 16th. Leerink Partners initiated coverage on shares of Celcuity in a research note on Monday, July 22nd. They issued an “outperform” rating and a $29.00 price objective for the company. Needham & Company LLC restated a “buy” rating and issued a $23.00 price objective on shares of Celcuity in a research note on Thursday, August 15th. Lifesci Capital initiated coverage on shares of Celcuity in a research note on Monday, August 26th. They issued an “outperform” rating and a $27.00 price objective for the company. Finally, Stifel Nicolaus reduced their price objective on shares of Celcuity from $40.00 to $39.00 and set a “buy” rating for the company in a research note on Thursday, August 15th.

Celcuity Price Performance

NASDAQ CELC opened at $15.93 on Wednesday. The company has a quick ratio of 14.95, a current ratio of 14.95 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $589.89 million, a PE ratio of -5.73 and a beta of 0.76. The company has a 50 day moving average price of $16.96 and a two-hundred day moving average price of $16.98. Celcuity has a 12-month low of $8.39 and a 12-month high of $22.19.

Celcuity (NASDAQ:CELC) last posted its earnings results on Wednesday, August 14th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.09. During the same quarter last year, the firm earned ($0.66) earnings per share. As a group, equities analysts predict that Celcuity will post -2.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Celcuity

Several large investors have recently bought and sold shares of the stock. Quest Partners LLC increased its holdings in Celcuity by 31.3% in the 2nd quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock valued at $95,000 after buying an additional 1,379 shares during the period. BNP Paribas Financial Markets increased its holdings in Celcuity by 78.5% in the 1st quarter. BNP Paribas Financial Markets now owns 8,937 shares of the company’s stock valued at $193,000 after buying an additional 3,930 shares during the period. Pale Fire Capital SE increased its holdings in Celcuity by 38.4% in the 4th quarter. Pale Fire Capital SE now owns 14,409 shares of the company’s stock valued at $210,000 after buying an additional 4,000 shares during the period. Commonwealth Equity Services LLC increased its holdings in Celcuity by 9.9% in the 2nd quarter. Commonwealth Equity Services LLC now owns 16,624 shares of the company’s stock valued at $272,000 after buying an additional 1,500 shares during the period. Finally, Wealth Enhancement Advisory Services LLC increased its holdings in Celcuity by 7.8% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 22,030 shares of the company’s stock valued at $361,000 after buying an additional 1,600 shares during the period. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.